Results 151 to 160 of about 133,046 (390)

Immunosuppressive properties of sera and urine dialysates from kidney-graft recipients treated with azathioprine, prednisolone, and niridazole [PDF]

open access: bronze, 1977
Brett Jones   +6 more
openalex   +1 more source

Impact of biologic induction dose and concomitant drugs on anti‐drug antibody formation in a pediatric IBD cohort with high Hispanic representation

open access: yesJPGN Reports, EarlyView.
Abstract Objectives The use of biologic therapy is increasing in pediatric patients with inflammatory bowel disease (IBD). However, efficacy may be compromised by increased drug clearance and anti‐drug antibodies (ADAs). Historically, concomitant immunomodulator therapy (CIT) has been used to prevent ADA formation. Pediatric studies evaluating CIT have
Kenneth Grant   +3 more
wiley   +1 more source

Elevated tissue transglutaminase immunoglobulin A: Celiac disease or polytypic plasmacytosis?

open access: yesJPGN Reports, EarlyView.
Abstract We report a case of an adolescent girl post cardiac transplant with hypergammaglobulinemia and presumed celiac disease (CD), who had a persistently elevated anti‐tissue transglutaminase immunoglobulin A despite a gluten free diet. Refractory CD and Crohn's disease were excluded.
Andrew Turunen   +4 more
wiley   +1 more source

Medical management of inflammatory bowel disease [PDF]

open access: yes, 1999
Patients who have recently been diagnosed as suffering from inflammatory bowel disease face two disturbing realities: firstly the true cause of the disease has not yet been defined and secondly the long term prognosis is unpredictable.
Pullicino, Edgar
core  

Azathioprine and warts. [PDF]

open access: yesAnnals of the Rheumatic Diseases, 1990
G Philippart, P Moens, C Moens
openaire   +2 more sources

Targeting JAK‐1 in Disseminated Cutaneous Lichen Planus

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT We report the case of a 63‐year‐old woman with an exuberant and recalcitrant clinical presentation of LP who had an excellent response to 200 mg/day abrocitinib, a JAK‐1 inhibitor, after failure to other commonly used therapies. The efficacy of JAK inhibitors in lichen planus is supported by small case series and isolated case reports. Further
F. Barbosa, L. Siems, D. Luz, A. Duarte
wiley   +1 more source

Home - About - Disclaimer - Privacy